NCT02434575

Brief Summary

This registry study enables us to collect data on the treatment of LUTS using prostate artery embolisation (PAE), and other surgical methods to answer the following questions posed by NICE in 2013:

  • Is PAE a safe and effective treatment option for LUTS caused by prostate enlargement?
  • How does PAE compare with conventional surgical treatments? This will primarily be a surgical procedure called transurethral resection of the prostate (TURP) (see below).
  • Which patients would most benefit from PAE over the other treatment options?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
318

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2014

Typical duration for all trials

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

March 20, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 5, 2015

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2016

Completed
Last Updated

February 7, 2020

Status Verified

February 1, 2020

Enrollment Period

2.4 years

First QC Date

March 20, 2015

Last Update Submit

February 6, 2020

Conditions

Keywords

Lower Urinary Tract SymptomsProstatic artery embolisationTransurethral resection of the prostateBenign prostatic hyperplasiaBenign prostatic enlargement

Outcome Measures

Primary Outcomes (1)

  • IPSS change for PAE patients, from baseline 12 months post procedure

    Comparison of IPSS questionnaire score at baseline at 12 months post-PAE procedure

    12 months

Secondary Outcomes (6)

  • IPSS comparison of PAE with TURP, 12 months post-procedure

    12 Months

  • Safety of PAE procedure - Number of patients with adverse events up to 12 months post-procedure

    12 months

  • IPSS comparison of other treatments (HoLEP, Open prostatectomy) to PAE, 12 months post-procedure

    12 months

  • IIEF comparison of TURP, HoLEP and Open prostatectomy to PAE, 12 months post-procedure.

    12 months

  • Prostate volume comparison of TURP, HoLEP and Open prostatectomy to PAE, 12 months post-procedure.

    12 months

  • +1 more secondary outcomes

Study Arms (3)

PAE

Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.

TURP

Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.

Other

Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Men with LUTS BPE who have consented to PAE, TURP, Open prostatectomy or laser surgery at a participating UK site.

You may qualify if:

  • Men with LUTS who have consented for PAE, TURP, open prostatectomy or laser surgery at a participating site
  • Able to read, write and understand English
  • Capable of giving informed written consent

You may not qualify if:

  • Not able to read, write or understand English
  • Not able/willing to provide informed written consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

Colchester Hospital University NHS Foundation Trust

Colchester, Essex, United Kingdom

Location

East Kent Hospitals University NHS Foundation Trust

Canterbury, Kent, United Kingdom

Location

University Hospitals Birmingham NHS Foundation Trust

Birmingham, United Kingdom

Location

The Royal Bournemouth and Christchurch NHS Foundation Trust

Bournemouth, United Kingdom

Location

University Hospitals Coventry & Warwickshire NHS

Coventry, United Kingdom

Location

Frimley Park Hospital NHS Found Trust

Frimley, United Kingdom

Location

NHS Greater Glasgow and Clyde

Glasgow, United Kingdom

Location

Hull and East Yorkshire Hospitals NHS Trust

Hull, United Kingdom

Location

Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom

Location

Imperial College Healthcare NHS Trust

London, United Kingdom

Location

Central Manchester University Hospitals NHS Foundation Trust

Manchester, United Kingdom

Location

Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, United Kingdom

Location

Oxford University Hospitals NHS Trust

Oxford, United Kingdom

Location

Plymouth Hospitals NHS Trust

Plymouth, United Kingdom

Location

University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

Location

University Hospital North Staffordshire NHS Trust

Stoke-on-Trent, United Kingdom

Location

Royal Cornwall Hospitals NHS Trust

Truro, United Kingdom

Location

Related Publications (2)

  • Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, Modi S, Dyer J, Harris M, Carolan-Rees G, Hacking N. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018 Aug;122(2):270-282. doi: 10.1111/bju.14249. Epub 2018 May 6.

  • Patel N, Yung N, Vigneswaran G, de Preux L, Maclean D, Harris M, Somani B, Bryant T, Hacking N, Modi S. 1-year cost-utility analysis of prostate artery embolization (PAE) versus transurethral resection of the prostate (TURP) in benign prostatic hyperplasia (BPH). BMJ Surg Interv Health Technol. 2021 Nov 10;3(1):e000071. doi: 10.1136/bmjsit-2020-000071. eCollection 2021.

MeSH Terms

Conditions

Lower Urinary Tract SymptomsProstatic Hyperplasia

Condition Hierarchy (Ancestors)

Urological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsProstatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Cedar Director

Study Record Dates

First Submitted

March 20, 2015

First Posted

May 5, 2015

Study Start

July 1, 2014

Primary Completion

December 1, 2016

Study Completion

December 31, 2016

Last Updated

February 7, 2020

Record last verified: 2020-02

Locations